Biometrics & Data Science

Evaluating Time In Range Potential in Reducing Costs of Diabetes Care

OccamPoint located in Burlington, CA

Estimated 30.3 million Americans, or 9.4% of the US population has diabetes, with the healthcare costs reaching nearly $404 billion annually (The economic burden of elevated blood glucose Level in 2017: diagnosed and undiagnosed diabetes, gestational diabetes mellitus and prediabetes. Diabetes Care, 2019). Its major complications include heart disease, visual impairment, kidney failure, neuropathy, and a spectrum of…

Read More

Precision Pathology as Part of Precision Medicine: Are We Optimizing Patients’ Interests in Prioritizing Use of Limited Tissue Samples?

OccamPoint

Insufficient sample tissue and conflicting legal and regulatory requirements increasingly pose a practical obstacle for the implementation of precision medicine testing for patient treatment protocols and clinical trial research. While shift away from a single biomarker testing to next generation sequencing and advances in science and practice of pathology provide some solutions to the problem,…

Read More

Complex Innovative Trial Designs Pilot Program

OccamPoint

FDA announces a set of presentations and a pilot program to advance Complex Innovative Clinical Trial Designs (CIDs) as a part of PDUFA VI (Aug 2017). The initiative is aimed to facilitate the discussion about the use of CIDs in drug development and regulatory decision-making. It covers the use of complex adaptive, Bayesian and other…

Read More

AI Applications in the Pharma Industry

OccamPoint

A captivating debate is unfolding regarding applications of AI in pharma. In his book, AI Superpowers, and recent appearance on CBS 60 Minutes, Kai Fu Lee inspiringly represents the vision that AI will supersede all human decision-making one day. However, while initially met with significant enthusiasm, most attempts to incorporate AI into drug discovery and…

Read More